Syros tyme technologies
WebSep 16, 2024 · Syros is redefining the power of small molecules to control the expression of genes. Based on its unique ability to elucidate regulatory regions of the genome, Syros … WebSYRS (Syros Pharmaceuticals) Other Long Term Assets as of today (April 14, 2024) is $8.43 Mil. Other Long Term Assets explanation, calculation, historical data
Syros tyme technologies
Did you know?
WebJul 5, 2024 · Syros to Raise Approximately $190 Million Through Merger with TYME Technologies and Concurrent Private Placement Combined Company Will Operate as Syros Pharmaceuticals and Continue to Advance Syros' Ongoing Clinical Programs Syros Expects to Have Cash Into 2025; At Least a Year Past SELECT-MDS-1 Pivotal Data WebSep 15, 2024 · Syros Pharmaceuticals, Inc. SYRS, a leader in the development of medicines that control the expression of genes, and Tyme Technologies, Inc. TYME today announced the results of the special ...
WebSep 16, 2024 · CAMBRIDGE, Mass., September 16, 2024 -- ( BUSINESS WIRE )--Syros Pharmaceuticals, Inc. (NASDAQ:SYRS), a leader in the development of medicines that … WebSyros Pharmaceuticals is set to acquire a New Jersey biotech firm called Tyme Technologies Inc., extending its cash runway into 2025 at a time when biotech stocks are …
WebBy merging with the floundering Tyme Technologies and tapping investors including Flagship Pioneering, the gene expression biotech has extended its cash runway out into 2025. Syros buys Tyme ... WebJul 5, 2024 · In the merger, Syros expects to issue approximately 74.3 million shares of its common stock to TYME stockholders to acquire TYME’s expected net cash at closing and …
WebTYME is an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™) that are intended to be effective across a broad range of solid tumors and hematologic cancers, while also maintaining patients’ quality of life through relatively low toxicity profiles.
WebJul 5, 2024 · Per the terms, Syros ( SYRS) will issue ~74.3M shares of its common stock to TYME investors, and TYME stockholders are entitled to nearly 0.4312 shares of Syros ( SYRS) common stock for... michaelle thixton linkedinWebSep 15, 2024 · -- Combined Company to Trade on Nasdaq Under Ticker “SYRS” -- -- Syros Announces 1-for-10 Reverse Stock Split of Common Stock -- Syros Pharmaceuticals, Inc. (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, and Tyme Technologies, Inc. … how to change mic gainWebSep 15, 2024 · Shareholders of Syros Pharmaceuticals (SYRS) and Tyme Technologies (TYME) on Thursday voted in favor of the merger between the two biotech companies.SYRS and TYME stock gained more... michael letorney insuranceWebPublished: Sept. 15, 2024 at 5:11 p.m. ET. By Stephen Nakrosis. Shares of Syros Pharmaceuticals Inc. and Tyme Technologies Inc. were higher in Thursday's after-hours trading, following news the ... how to change mic gain windows 10WebAbout Tyme Technologies, Inc. TYME is an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™) that are intended to be effective across a … michael lethbridgeWebSep 15, 2024 · Syros and Tyme Technologies Announce Stockholder Approval of Merger TYME Technologies, Inc. September 15, 2024, 4:13 PM · 10 min read TYME Technologies, … how to change meta quest emailWebBy merging with the floundering Tyme Technologies and tapping investors including Flagship Pioneering, the gene expression biotech has extended its cash runway out into … how to change metro pcs pin